Combined PARP inhibitors and small molecular inhibitors in solid tumor treatment (Review)
Cancers | Free Full-Text | Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors
Frontiers | The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
Biomedicines | Free Full-Text | Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance
Cancers | Free Full-Text | PARP Inhibitors in Melanoma—An Expanding Therapeutic Option?
How PARP inhibitors (PARPi) work - YouTube
Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy - Yusoh - 2020 - ChemMedChem - Wiley Online Library
PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications | Molecular Cancer | Full Text
Mechanisms of resistance to PARP inhibitors. Cancer cells develop... | Download Scientific Diagram
Epigenetic marker contributes to PARP inhibitor resistance | Center for Cancer Research
Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review - Gynecologic Oncology
FDA Approves Olaparib, Rucaparib to Treat Prostate Cancer - NCI
Focus on suppressive macrophages may boost effects of PARP inhibitors
PARP inhibitors mechanisms of action and resistance. The left part of... | Download Scientific Diagram
PARP inhibitors stumble in breast cancer | Nature Biotechnology
PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells: Trends in Cell Biology
PARP inhibitor combination therapy - ScienceDirect
PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review)
Mode of Action | OncologyPRO
Nausea and Vomiting: Managing Side Effects From PARP Inhibitors
JCI - The evolving landscape of predictive biomarkers of response to PARP inhibitors
PARP inhibitor - Wikipedia
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action | Science Translational Medicine
The Latest Developments on PARP Inhibitors for Prostate Cancer Treatment
